To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...

Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

Rural men had almost twice the risk of prostate cancer biochemical recurrence as urban men in the US. Patients living in rural areas may be at an increased risk for prostate cancer biochemical ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

June 22, 2011 — Patients who smoke at the time of their prostate cancer diagnosis are at higher risk for disease-specific mortality. In addition, smoking at the time of a prostate cancer diagnosis is ...

Anyone discouraged by the continued absence of a prostate cancer screening programme, the difficulties in getting a clear ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...